The University of Manchester held its first Innovation Festival in October 2026, drawing 3,000 attendees across 25 events and featuring 116 speakers who discussed innovation, investment and collaboration. The festival, which ran from 5 to 9 October, underscored a central theme: the university's ability to generate impact depends heavily on partnerships with businesses, investors and other cities.
According to the University of Manchester, Professor John Holden, Vice-President for Civic Engagement and Innovation, told the Partnership Excellence Awards on 7 October: "No matter how good we are as a university, we can only have the scale of impact we want by working with others." Holden also noted that over the past year, the university formed 191 new business partnerships — roughly one for every working day. The university ranks second in the UK for contract research with small and medium-sized enterprises and fifth for industry research funding, the university reported.
A recurring theme among those involved in successful partnerships was the importance of time and trust. Professor Simon Luckman, Brackenbury Chair of Physiology at the university, has collaborated with pharmaceutical company Eli Lilly for about 20 years, most recently with Dr Amy Worth on research into how GLP-1 drugs affect food cravings. Luckman said at the awards that trust, built over two decades, enables "very open and honest exchange." He contrasted this with collaborations where each side withholds information, calling those "disastrous."
Professor Alan Dickson, Director of the Centre of Excellence in Biopharmaceuticals and Professor of Biotechnology, described building partnerships over an even longer period. In 1990, he was one of very few biologists at Manchester working with industry. Over the following decades, he helped create networks that eventually led to strategic partnerships with AstraZeneca's biologics division and FUJIFILM. Dickson said these partnerships work because each side contributes what the other lacks. "I'm just an academic. I can't manufacture these things," he said of cell and gene therapies. Industry provides scale-up, regulatory expertise and a route to patients. Dickson also noted that working with companies taught him project management skills he did not have before.
The festival also highlighted partnerships with smaller businesses. The top prize, Partnership Excellence of the Year, went to Saraco Industries, which has worked with Professor Sarah Cartmell and Professor Andrew McBain on developing plastic-free clinical disinfection wipes. The company also won the Small Business award.
Some partnerships provide access to communities. Dr Joanne Tippett's RoundView project, which was shortlisted at the awards, collaborated with Manchester City of Literature to test a game-based sustainability tool in libraries and schools, reaching thousands of children, parents, teachers and librarians. Tippett said a good partnership requires "the ability to try something out, find out it doesn't work, and learn from that and keep going."
The university has established Unit M, its innovation arm, to help external partners find the right contacts within the institution. Geraint North, who helped set up semiconductor manufacturer Arm's site in Manchester, said at a panel on 8 October that Unit M has expanded Arm's connections beyond computer science to include robotics engineers and future-of-work researchers, as the company now manufactures its own chips.
For founders, navigating the range of support available can be challenging. Veronica Ferguson, Head of Regional Operations at Innovate UK's ICURe programme, said at the Powerhouse of Innovation Showcase that bringing providers together helps founders find "the person that can give them the next step." ICURe encourages researchers to test market demand through up to 100 conversations with customers, regulators and competitors. Its latest cohort will work with materials researchers at the Henry Royce Institute, which offers facilities and expertise across 11 partner sites, free for researchers and subsidised for small businesses and spinouts.
Investment in the north is growing, and investors bring more than capital. Northern Gritstone has £382 million to invest in science and technology companies from Manchester, Leeds, Liverpool and Sheffield. Investment Director Cassie Docherty said at a summit panel that the firm's role extends beyond writing cheques: "We're capital, but we're there to help," including finding talent and shaping strategy. Pairing an academic founder with an experienced executive chair, she argued, is one of the best ways to navigate the "valley of death" between lab and market.
Professor Sam Butterworth, Professor of Medicinal Chemistry, described how his drug discovery project required years of translational funding before attracting investors. An Innovate UK investor partnership grant provided the "oomph" to persuade backers to commit. Northern Gritstone co-invested to form Apini Therapeutics, which raised £9 million in 2024 to develop a therapy for inflammatory diseases and is working toward clinical trials.
The university is also launching its own Founders Fund, aiming to raise £10 million, which will begin making pre-seed investments in 2027. Niaz Rayan's agritech spinout Spore Sense, which detects crop disease before symptoms appear, progressed from an Ideas with Impact Award to a commercial development grant and now its first pre-seed round, with an eye on investors beyond Manchester.
The Cambridge x Manchester Partnership, the UK's first deliberately designed cross-city innovation partnership, aims to replace rivalry with collaboration. Director Faye Holland said at the partnership's Innovation Summit: "Our postcodes compete, our councils compete, our combined authorities compete. I wonder why we don't use the word 'co-opetition', where we bring collaboration and competition together in a really positive way." The partnership is building an 'innovation passport', due by the end of the year, to give founders in one city easier access to space, accelerators, investors and corporate partners in the other. A joint investment prospectus for the two cities is also in development, Shaun Grady, UK Chair of AstraZeneca, told the summit.
Professor Dame Jessica Corner, Executive Chair of Research England, which funds the partnership, described it as an experiment. She said Cambridge has one of the strongest innovation ecosystems in the world but is close to overheating. "Could you drive the overheat into another city, Manchester, in order to grow the opportunity there? That's the experiment, and we'll see what happens." She said she will judge it on hard outcomes: venture capital moving north and investment that would not otherwise have happened, with early signs already emerging.
For students, the festival's emphasis on partnerships signals opportunities beyond the classroom. The university's strong industry connections, its new Founders Fund, and cross-city initiatives like the Cambridge x Manchester Partnership could translate into more internships, research collaborations, and startup support. The festival itself, with its 3,000 attendees and 25 events, demonstrated the scale of these opportunities, though the university did not provide specific data on how many students participated or what direct benefits they may see.